Journal article
Thalidomide‐prednisone maintenance following autologous stem cell transplant for Multiple Myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10
Abstract
Venous thromboembolism (VTE) has an increased incidence in patients with multiple myeloma (MM), especially during chemotherapy. Mechanisms including upregulation of procoagulant factors, such as factor VIII, have been postulated. The National Cancer Institute of Canada Clinical Trials Group MY.10 phase III clinical trial compared thalidomide-prednisone to observation for 332 patients with MM post-autologous stem cell transplantation (ASCT), …
Authors
Kovacs MJ; Davies GA; Chapman JW; Bahlis N; Voralia M; Roy J; Kouroukis CT; Chen C; Belch A; Reece D
Journal
British Journal of Haematology, Vol. 168, No. 4, pp. 511–517
Publisher
Wiley
Publication Date
2 2015
DOI
10.1111/bjh.13176
ISSN
0007-1048
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsAntithrombin IIICombined Modality TherapyFactor VIIIFemaleFibrin Fibrinogen Degradation ProductsFollow-Up StudiesHematopoietic Stem Cell TransplantationHumansMaintenance ChemotherapyMaleMiddle AgedMultiple MyelomaPeptide HydrolasesPrednisoneThalidomideThrombinThrombophiliaTransplantation, AutologousVenous Thromboembolism